The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

4/BA.5 and original strains of SARS-CoV-2, compared to mRNA-1273.222, Moderna’s previously approved bivalent Omicron BA.4/BA.5-targeting COVID vaccine. Per management, the benefit was primarily ...

In a record-breaking span of just 11 months, Moderna created, developed, manufactured, and got regulatory authorization for mRNA-1273, a two-dose COVID-19 vaccine that is one of the first two mRNA ...

1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...

They included participants who received mRNA vaccines (BNT162b2 or mRNA-1273) or adenoviral vector vaccines (Ad26.COV2.S) from January 2022 to December 2023. Those who hadn’t received ...